The effect of early application of Tirofiban on CRP levels in patients with acute myocardial infarction after emergency percutaneous coronary intervention
- VernacularTitle:早期应用替罗非班对急性心肌梗死急症PCI术后C反应蛋白水平的影响
- Author:
Hongbing XIAO
;
Jun GU
;
Dadong ZHANG
- Publication Type:Journal Article
- Keywords:
myocardial infarction;
angioplasty;
Tirofiban
- From:
Journal of Interventional Radiology
2010;19(2):101-104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of Tirofiban on CRP levels in patients with acute myocardial infarction (AMI) after primary emergency percutaneous coronary intervention (PCI). Methods Eighty-four AMI patients admitted on emergency were randomly divided into two groups: (1) early-treated group (n=45), immediately receiving Tirofiban intravenously on admission and (2) late-treated group (n=39), receiving Tirofiban intravenously after coronary angiography was performed. TIMI grading before and after PCI in beth groups were compared, CRP levels before and three days after PCI were estimated. The major adverse cardiovascular events (MACEs) occurred during hospitalization and following-up period of three months were recorded. Results Before PCI, TIMI grade 3 forward flow rate in early-treated group was significantly higher than that in late-treated group, while no significant difference existed between two groups after PCI. Three days after PCI, CRP level in early-treated group was markedly lower than that in late-treated group. During hospitalization, the occurrence of MACEs in early-treated group was lower than that in late-treated group, while no marked difference was found between two groups during the following-up period of three months. Conclusion In treating AMI patients with primary PCI, Tirofiban should be used as early as possible, which is safe and effective for PCI and can also significantly improve forward blood flow in target vessels, decrease the ClIP level and reduce the occurrence of MACEs during hospitalization.
